[go: up one dir, main page]

CA2817250A1 - Nouvelles compositions et utilisations d'agents hypotenseurs dans le traitement du cancer - Google Patents

Nouvelles compositions et utilisations d'agents hypotenseurs dans le traitement du cancer Download PDF

Info

Publication number
CA2817250A1
CA2817250A1 CA2817250A CA2817250A CA2817250A1 CA 2817250 A1 CA2817250 A1 CA 2817250A1 CA 2817250 A CA2817250 A CA 2817250A CA 2817250 A CA2817250 A CA 2817250A CA 2817250 A1 CA2817250 A1 CA 2817250A1
Authority
CA
Canada
Prior art keywords
ahcm
cancer
agent
administered
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2817250A
Other languages
English (en)
Inventor
Rakesh Kumar Jain
Yves Boucher
Vikash Pal Singh Chauhan
Benjamin Diop-Frimpong
Stephen Krane
Alan L. Crane
Robert Samuel Langer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
XTUIT PHARMACEUTICALS Inc
Original Assignee
General Hospital Corp
XTUIT PHARMACEUTICALS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp, XTUIT PHARMACEUTICALS Inc filed Critical General Hospital Corp
Publication of CA2817250A1 publication Critical patent/CA2817250A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA2817250A 2010-11-18 2011-11-18 Nouvelles compositions et utilisations d'agents hypotenseurs dans le traitement du cancer Abandoned CA2817250A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41519210P 2010-11-18 2010-11-18
US61/415,192 2010-11-18
US201161438240P 2011-01-31 2011-01-31
US61/438,240 2011-01-31
PCT/US2011/061510 WO2012068531A2 (fr) 2010-11-18 2011-11-18 Nouvelles compositions et utilisations d'agents hypotenseurs dans le traitement du cancer

Publications (1)

Publication Number Publication Date
CA2817250A1 true CA2817250A1 (fr) 2012-05-24

Family

ID=46084685

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2817250A Abandoned CA2817250A1 (fr) 2010-11-18 2011-11-18 Nouvelles compositions et utilisations d'agents hypotenseurs dans le traitement du cancer

Country Status (7)

Country Link
EP (1) EP2640359A4 (fr)
JP (2) JP2014505666A (fr)
CN (1) CN103561726A (fr)
AU (1) AU2011329638C1 (fr)
CA (1) CA2817250A1 (fr)
RU (2) RU2018102375A (fr)
WO (1) WO2012068531A2 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4903036B2 (ja) 2003-01-06 2012-03-21 アンジオケム・インコーポレーテッド 血液脳関門を通過する担体としてのアプロチニンおよび類似体
WO2007009229A1 (fr) 2005-07-15 2007-01-25 Angiochem Inc. Utilisation de polypeptides de l'aprotinine comme vehicules dans des conjugues pharmaceutiques
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
WO2009127072A1 (fr) 2008-04-18 2009-10-22 Angiochem Inc. Compositions pharmaceutiques de paclitaxel, d'analogues de paclitaxel ou de conjugués de paclitaxel et procédés de préparation et d'utilisation correspondants
WO2010043047A1 (fr) 2008-10-15 2010-04-22 Angiochem Inc. Conjugués d'agonistes de glp-1 et leurs utilisations
CA2740317A1 (fr) 2008-10-15 2010-04-22 Angiochem Inc. Conjugues de l'etoposide et de la doxorubicine pour l'administration de medicaments
US9914754B2 (en) 2008-12-05 2018-03-13 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
AU2009327267A1 (en) 2008-12-17 2011-07-14 Angiochem, Inc. Membrane type-1 matrix metalloprotein inhibitors and uses thereof
ES2729261T3 (es) 2009-04-20 2019-10-31 Angiochem Inc Tratamiento del cáncer de ovario utilizando un agente anticancerígeno conjugado con un análogo de Angiopep-2
WO2011000095A1 (fr) 2009-07-02 2011-01-06 Angiochem Inc. Conjugués peptidiques multimères et leurs utilisations
EP3939572B1 (fr) 2012-04-12 2024-03-27 Yale University Véhicules pour l'administration contrôlée d'agents pharmaceutiques différents
CA2872652A1 (fr) * 2012-05-07 2013-11-14 The General Hospital Corporation Nouvelles compositions et utilisations d'agents antihypertenseurs pour therapie anticancereuse
US9486503B2 (en) 2012-10-04 2016-11-08 Shionogi & Co., Ltd. Medicinal agent for suppressing malignant tumor metastasis
EA201590822A1 (ru) * 2012-11-02 2016-01-29 Фармасайкликс, Инк. Адъювантная терапия ингибитором киназы семейства tec
WO2014129914A1 (fr) * 2013-02-22 2014-08-28 Auckland Uniservices Limited Procédés de traitement
US8975290B2 (en) 2013-03-01 2015-03-10 Colorado State University Research Foundation Methods and compositions for enhancing an immune response, blocking monocyte migration, amplifying vaccine immunity and inhibiting tumor growth and metastasis
EP2961483A4 (fr) * 2013-03-01 2017-03-08 The Colorado State University Research Foundation Procédés et compositions permettant d'améliorer une réponse immunitaire, de bloquer la migration des monocytes, d'amplifier l'immunité d'un vaccin et d'inhiber la croissance d'une tumeur et des métastases
TW201532603A (zh) * 2013-04-10 2015-09-01 Public University Corp Nara Medical University 肝癌之預防及／或治療劑
WO2015026813A1 (fr) * 2013-08-19 2015-02-26 Taris Biomedical Llc Dispositifs d'administration de médicament à multiples unités et procédés
CN105792823B (zh) * 2013-11-01 2019-11-12 皮特尼制药股份有限公司 治疗恶性肿瘤的药物组合
CN105848649B (zh) 2013-11-01 2019-08-02 耶鲁大学 用于免疫疗法的模块化粒子
KR20180021684A (ko) * 2015-04-25 2018-03-05 더 제너럴 하스피털 코포레이션 암 치료용 항-기피주성제와 면역요법제 조합 요법 및 조성물
EP3307326B9 (fr) 2015-06-15 2021-02-24 Angiochem Inc. Procédés de traitement d'une carcinomatose leptoméningée
CN105326812A (zh) * 2015-10-28 2016-02-17 南昌大学 一种索拉菲尼固体脂质纳米粒及其制备方法
US11433136B2 (en) 2015-12-18 2022-09-06 The General Hospital Corporation Polyacetal polymers, conjugates, particles and uses thereof
JP6956091B2 (ja) * 2016-08-26 2021-10-27 哲治 奥野 微小ナノ化薬剤およびその利用
WO2018064092A1 (fr) * 2016-09-27 2018-04-05 Vertex Pharmaceuticals Incorporated Méthode de traitement du cancer utilisant une combinaison d'agents endommageant l'adn et d'inhibiteurs de la dna-pk
CN108358995B (zh) * 2017-01-25 2021-07-06 四川大学 CP-iRGD多肽、iDPP纳米粒、载药复合物及其制备方法和应用
RU2724398C1 (ru) * 2019-09-03 2020-06-23 Федеральное государственное бюджетное образовательное учреждение высшего образования "Алтайский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ определения степени агрессивности течения рака легкого.
EP4072525A1 (fr) 2019-12-13 2022-10-19 Massachusetts Institute of Technology Barrières tissulaires synthétiques et utilisations associées
EP3842099A1 (fr) * 2019-12-23 2021-06-30 Albert-Ludwigs-Universität Freiburg Utilisation de losartan pour le traitement de maladies fibrotiques, en particulier l'épidermolyse bulleuse
US20230390248A1 (en) * 2020-10-26 2023-12-07 Korea Institute Of Radiological & Medical Sciences Composition for enhancing tumor penetration of anticancer drug, comprising losartan as active ingredient, and use thereof
CN112933235A (zh) * 2021-04-07 2021-06-11 北京蛋白质组研究中心 靶向soat1蛋白的化合物在制备预防和/或治疗肝癌药物中的应用
CN115317627B (zh) * 2022-08-26 2023-10-24 江西中医药大学 Abt-510肽在制备肿瘤显像剂中的应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
ES2091684T3 (es) 1992-11-13 1996-11-01 Idec Pharma Corp Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b.
MY131805A (en) * 1997-09-18 2007-09-28 Biogen Idec Inc Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis.
US6719977B1 (en) * 1998-02-12 2004-04-13 The General Hospital Corporation Methods to potentiate cancer therapies
DE10144980B4 (de) 2001-09-12 2004-06-03 Webasto Vehicle Systems International Gmbh Führungsvorrichtung für einen Deckel eines zu öffnenden Fahrzeugdaches
CA2563617A1 (fr) * 2004-04-20 2005-11-03 Rnd Pharmaceuticals Compositions pharmaceutiques et methodes d'utilisation de medicaments et de derives de cyclo-oxygenase-2 lipophiles a substitution silicium
US20080299205A1 (en) 2004-07-19 2008-12-04 Mayer Lawrence D Particulate Constructs For Release of Active Agents
TWI386225B (zh) 2004-12-23 2013-02-21 Alcon Inc 用於治療眼睛病症的結締組織生長因子（ＣＴＧＦ）ＲＮＡ干擾（ＲＮＡｉ）抑制技術
WO2006077901A1 (fr) 2005-01-20 2006-07-27 Shionogi & Co., Ltd. Inhibiteur de l’expression du ctgf
PT3520815T (pt) 2005-02-08 2022-02-02 Genzyme Corp Anticorpos contra tgfbeta
SG166775A1 (en) * 2005-02-18 2010-12-29 Abraxis Bioscience Llc Combinations and modes of administration of therapeutic agents and combination therapy
US7846908B2 (en) 2006-03-16 2010-12-07 Alnylam Pharmaceuticals, Inc. RNAi modulation of TGF-beta and therapeutic uses thereof
US20090012052A1 (en) * 2006-11-09 2009-01-08 Ore Pharmaceuticals Inc. Method for treating er+ breast cancer
US20090220588A1 (en) * 2008-02-21 2009-09-03 Massachusetts Institute Of Technology Simultaneous Delivery of Receptors and/or Co-Receptors for Growth Factor Stability and Activity
US20100029734A1 (en) * 2008-05-06 2010-02-04 Ore Pharmaceuticals Inc. Methods for breast cancer screening and treatment
WO2010005726A2 (fr) 2008-06-16 2010-01-14 Bind Biosciences Inc. Nanoparticules polymères thérapeutiques avec inhibiteurs de mtor et procédés de fabrication et d’utilisation associés
JP2012501965A (ja) 2008-06-16 2012-01-26 バインド バイオサイエンシズ インコーポレイテッド 薬剤を装填したポリマーナノ粒子及びその製造方法と使用方法
WO2010005740A2 (fr) 2008-06-16 2010-01-14 Bind Biosciences, Inc. Procédés pour la préparation de copolymères diblocs fonctionnalisés avec un agent de ciblage destinés à être utilisés dans la fabrication de nanoparticules ciblées thérapeutiques
US8563041B2 (en) 2008-12-12 2013-10-22 Bind Therapeutics, Inc. Therapeutic particles suitable for parenteral administration and methods of making and using same
EP2379064B1 (fr) 2008-12-15 2020-02-26 Pfizer Inc. Longues nanoparticules circulantes pour la libération prolongée d'agents thérapeutiques
DE202009018883U1 (de) 2009-04-24 2014-03-12 BSH Bosch und Siemens Hausgeräte GmbH Programmwähler für ein Hausgerät, insbesondere für eine Waschmaschine

Also Published As

Publication number Publication date
AU2011329638C1 (en) 2017-04-27
EP2640359A4 (fr) 2015-11-04
JP2014505666A (ja) 2014-03-06
RU2013127625A (ru) 2014-12-27
WO2012068531A3 (fr) 2013-11-28
AU2011329638B2 (en) 2016-10-13
EP2640359A2 (fr) 2013-09-25
CN103561726A (zh) 2014-02-05
RU2018102375A (ru) 2019-02-21
AU2011329638A1 (en) 2013-05-30
JP2017101056A (ja) 2017-06-08
WO2012068531A2 (fr) 2012-05-24

Similar Documents

Publication Publication Date Title
AU2011329638C1 (en) Novel compositions and uses of anti-hypertension agents for cancer therapy
US20130287688A1 (en) Novel compositions and uses of anti-hypertension agents for cancer therapy
AU2018200448A1 (en) Novel compositions and uses of anti-hypertension agents for cancer therapy
WO2016140714A1 (fr) Nouvelles compositions et utilisations d'agents de metformine
US11433136B2 (en) Polyacetal polymers, conjugates, particles and uses thereof
JP2024116286A (ja) ｉｎ ｖｉｖｏでの核酸発現のためのシステム及び方法
US9867842B2 (en) Methods and compositions for reversing disruption of the glycocalyx, inflammation, and oxidative damage
JP2024537794A (ja) ヘテロ芳香族大環状エーテル化合物を使用して固形腫瘍を治療する方法
US20170056504A1 (en) Method of extending half-life of crystaline antibodies
JP2022180464A (ja) 膵癌の治療
JP2022513517A (ja) 癌の処置又は予防において使用する為のキノリン誘導体
US20220218833A1 (en) Platelet-facilitated delivery of therapeutic compounds
JP2011068627A (ja) アテローム動脈硬化抑制剤
WO2022040341A1 (fr) Thérapie abscopale contre le cancer
US20240052012A1 (en) Platelet alpha-granules for delivery of multiple proteins
RU2811417C2 (ru) Производные хинолина для применения в лечении или предупреждении рака
WO2025110250A1 (fr) Protéine mfg-e8 modifiée
US20200147070A1 (en) Inducing phospholipidosis for enhancing therapeutic efficacy
BR122024023622A2 (pt) Uso de um composto derivado de quinolina para tratamento ou prevenção de câncer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20161102

FZDE Dead

Effective date: 20190529